Instil Bio Inc (TIL) Year-over-year earnings per share growth for the last twelve months

Brandmark of Instil Bio, Inc (TIL)

Instil Bio, Inc. (TIL) is a clinical-stage developer with no commercial sales, whose budget is entirely consumed by research. The company specializes in personalized therapy for solid tumors using modified patient lymphocytes. A strategic alliance with global laboratories is accelerating drug trials, which confirms the current quarterly EPS trend on the GURU.Markets chart, where 80.60 shows the current value of the metric.

Instil Bio Inc. (TIL) Year-over-year earnings per share growth for the last twelve months: for the period 07/04/2022 - 11/11/2026

Metric breakdowns and analytics for Instil Bio Inc (TIL)

- share price and expert price forecast:
Stock Price Instil Bio|TIL - Average Forecast Price
- market capitalization details:
Market Value Instil Bio, Inc|TIL - Total Company Value
- book capitalization data:
Net Assets per Single Share Instil Bio|TIL - Company Book Value|Market Cap to Net Assets Ratio instilbio.com|TIL - Aggregate Asset Value
- debt burden and liquidity indicators:
Total Debt to Capital Instil Bio, Inc.|TIL - Long-Term Indebtedness to Equity|Short-Term Debt to Capital Instil Bio, Inc.|TIL - Company Cumulative Debt|Debt to Book Capitalization Ratio Instil Bio, Inc|TIL - Company Long-Term Indebtedness|Company Short-Term Debts Instil Bio|Quick Liquidity Indicator instilbio.com
- earnings and market multiples details:
TIL - Final Profit|Future Profit Instil Bio, Inc.|TIL - Market Price to Net Income Ratio|Forward P/E Multiple Instil Bio, Inc|TIL - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Instil Bio, Inc|TIL - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Instil Bio|TIL - Earnings per share for the trailing year|Quarterly EPS earnings growth instilbio.com|TIL - Earnings growth in current year|Net earnings per share growth forecast for next year Instil Bio, Inc.
Comprehensive company analysis:Instil Bio, Inc.
Flagship merchandise of Instil Bio Inc

Effective cash flow management determines the survival of Instil Bio, Inc. (TIL) given its narrow development pipeline. This metric calculates the dynamics of net earnings per share, reflecting the actual return on capital. The indicator measures quarterly EPS growth, allowing for an assessment of the issuer's financial stability between reports. Analysis based on the quarterly EPS trajectory reveals the risks of cash gaps during restructuring. This protects the investor from overpaying for speculative assets.

Key competitors

LEGN: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Sana Biotechnology Inc (SANA)|Year-over-year earnings per share growth for the last twelve months Autolus Pharma|Year-over-year earnings per share growth for the last twelve months ALLO|Year-over-year earnings per share growth for the last twelve months Cartesian Therapeutics (RNAC)|Year-over-year earnings per share growth for the last twelve months CLLS (cellectis.com)|Caribou Biosciences, Inc. - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months GNTA|Century Therapeutics Inc - Quarterly EPS earnings growth|Net earnings per share growth for the trailing year Jasper Therapeutics (JSPR)|SNTI: Quarterly EPS earnings growth|Earnings per share growth in annualized terms for the last twelve months Adaptimmune Therapeutics (ADAP)|Year-over-year earnings per share growth for the last twelve months CERo Therapeutics Holdings, Inc.|Year-over-year earnings per share growth for the last 12 months TCRT (Alaunos)|Quarterly EPS earnings growth ACHL|CRGX - Earnings per share growth in annualized terms for the last twelve months|Poseida Therapeutics - Year-over-year net earnings per share growth for the last 12 months|Year-over-year earnings per one share growth for the last 12 months TSVT|GRCL: Year-over-year net earnings per share growth for the last 12 months